Filing Flows › Penumbra (PEN) › Embolization and Access revenue
Penumbra (PEN) Embolization and Access revenue by quarter
Penumbra's Embolization and Access revenue was $131M in Q3 2026 (third quarter 2026), -0.1% from Q2 2026. Over the last 6 quarters it ranged from $97.6M (Q1 2025) to $131M (Q2 2026).
| Quarter | Embolization and Access revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $131M | -0.1% | +11% |
| Q2 2026 | $131M | +8% | +20% |
| Q1 2026 | $121M | +2% | +24% |
| Q3 2025 | $118M | +8% | — |
| Q2 2025 | $109M | +12% | — |
| Q1 2025 | $97.6M | — | — |
Q3 2026 at a glance
Penumbra, Q3 2026: revenue $410M (+16% year over year), operating margin 12.4%, net earnings $42.3M, operating cash flow $41.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Penumbra's Embolization and Access revenue?
Penumbra's Embolization and Access revenue was $131M in Q3 2026 (third quarter 2026), -0.1% from Q2 2026.
How has Penumbra's Embolization and Access revenue changed?
Over the last 6 quarters it ranged from $97.6M (Q1 2025) to $131M (Q2 2026).